Peptide O-xylosyltransferase 1 (XYLT1)

Peptide O-xylosyltransferase 1 (XYLT1) is a Golgi-resident enzyme that catalyzes the initial and rate-limiting step in the biosynthesis of glycosaminoglycan (GAG) chains. It functions by transferring D-xylose from UDP-xylose to specific serine residues on proteoglycan core proteins, establishing the tetrasaccharide linker required for the assembly of chondroitin sulfate, dermatan sulfate, and heparan sulfate [3, 10, 12]. These proteoglycans are essential components of the extracellular matrix (ECM), playing vital roles in cell signaling, adhesion, and tissue integrity [10, 13]. XYLT1 expression is significantly upregulated in response to pro-fibrotic stimuli like TGF-beta1, making it a critical biomarker for myofibroblast differentiation and a therapeutic target for fibrotic diseases such as systemic sclerosis and liver cirrhosis [1, 3, 6]. Conversely, genetic mutations in XYLT1 are linked to severe skeletal disorders, including Desbuquois dysplasia type 2, highlighting its importance in bone development and homeostasis [8, 15]. While no specialized drugs are currently FDA-approved for this target, research is focused on small-molecule inhibitors to modulate pathological ECM remodeling [3].

Other names

Xylosyltransferase 1XT-IUDP-D-xylose:proteoglycan core protein 2-O-beta-D-xylosyltransferase 1Protein xylosyltransferase 1XT1

Competitive inhibition of the catalytic domain to prevent the transfer of xylose to core proteins; downregulation of XYLT1 mRNA expression to reduce myofibroblast-mediated extracellular matrix deposition [3, 12].